ABUS vs BXP
Arbutus Biopharma Corp (ABUS) versus Boston Properties Inc (BXP) — a side-by-side from cached financials, not a winner call.
Arbutus Biopharma Corp (ABUS) is a biotechnology company listed on NASDAQ.
Boston Properties Inc (BXP) is a reit - office company listed on US.
Latest reported ABUS revenue for 2024-12-31 was $6.2M. Net income was -$69.9M. Revenue was down 66.0% from 2023-12-31 to 2024-12-31. ABUS currently screens at market cap $883.0M and trailing P/E 5.4.
Latest reported BXP revenue for 2025-12-31 was $3.48B. Net income was $276.8M. Revenue was up 2.2% from 2024-12-31 to 2025-12-31. BXP currently screens at market cap $12.12B.
ABUS currently screens at market cap $883.0M and trailing P/E 5.4. BXP currently screens at market cap $12.12B.
Not investment advice. Open the ABUS and BXP stock pages for the full models.
Not investment advice.